

Title: Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER) (CAG-00468N)

Decision: The Centers for Medicare & Medicaid Services (CMS) established a National Coverage Determination (NCD) to cover tricuspid transcatheter edge-to-edge repair (T-TEER) for the treatment of symptomatic tricuspid regurgitation (TR) under Coverage with Evidence Development (CED). T-TEER is covered for Medicare patients with symptomatic TR when furnished according to a Food and Drug Administration (FDA) market-authorized indication and within a CMS-approved CED study. T-TEER is not covered for patients outside of a CMS-approved study. Nothing in this NCD would prevent coverage of T-TEER through NCD 310.1 (Clinical Trial Policy) or through an Investigational Device Exemption (IDE) study.

What this means: Coverage of T-TEER for TR was previously subject to Medicare Administrative Contractor (MAC) local coverage determinations, when applicable, or at the discretion of HealthPartners. T-TEER for TR will now be covered for individuals who meet the criteria outlined in the Medicare NCD. Please refer to the final decision memo for all coverage criteria.

Effective: July 2, 2025

This announcement can be found at: [Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation \(T-TEER\)](#)

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal.

H2462_90242 IR Approved 06/2015

H2422_90242 IR Approved 07/2015

H4882_90242 IR Approved 03/2018